136 related articles for article (PubMed ID: 37759675)
21. Total saponins from Rubus parvifolius L. inhibits cell proliferation, migration and invasion of malignant melanoma in vitro and in vivo.
Cao J; Zhao X; Ma Y; Yang J; Li F
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33111956
[TBL] [Abstract][Full Text] [Related]
22. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
[TBL] [Abstract][Full Text] [Related]
23. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
24. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
25. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
26. Casticin Induced Apoptosis in A375.S2 Human Melanoma Cells through the Inhibition of NF-[Formula: see text]B and Mitochondria-Dependent Pathways In Vitro and Inhibited Human Melanoma Xenografts in a Mouse Model In Vivo.
Shiue YW; Lu CC; Hsiao YP; Liao CL; Lin JP; Lai KC; Yu CC; Huang YP; Ho HC; Chung JG
Am J Chin Med; 2016; 44(3):637-61. PubMed ID: 27109154
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells.
Han S; Yan Y; Ren Y; Hu Y; Wang Y; Chen L; Zhi Z; Zheng Y; Shao Y; Liu J
Cancer Res; 2021 Jun; 81(11):2918-2929. PubMed ID: 34087780
[TBL] [Abstract][Full Text] [Related]
28. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
29. Phenethyl isothiocyanate inhibits in vivo growth of subcutaneous xenograft tumors of human malignant melanoma A375.S2 cells.
Ni WY; Lu HF; Hsu SC; Hsiao YP; Liu KC; Liu JY; Ji BC; Hsueh SC; Hung FM; Shang HS; Chung JG
In Vivo; 2014; 28(5):891-4. PubMed ID: 25189905
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
Li X; Li Z; Li X; Liu B; Liu Z
BMC Cancer; 2017 May; 17(1):357. PubMed ID: 28532456
[TBL] [Abstract][Full Text] [Related]
31. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
[TBL] [Abstract][Full Text] [Related]
32. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
Pedini F; De Luca G; Felicetti F; Puglisi R; Boe A; Arasi MB; Fratini F; Mattia G; Spada M; Caporali S; Biffoni M; Giuliani A; Carè A; Felli N
Mol Oncol; 2019 Sep; 13(9):1836-1854. PubMed ID: 31115969
[TBL] [Abstract][Full Text] [Related]
33. Metabolic imaging using hyperpolarized
Acciardo S; Mignion L; Lacomblez E; Schoonjans C; Joudiou N; Gourgue F; Bouzin C; Baurain JF; Gallez B; Jordan BF
J Cell Mol Med; 2020 Jan; 24(2):1934-1944. PubMed ID: 31833658
[TBL] [Abstract][Full Text] [Related]
34. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
35. Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
Xu Y; Zhang F; Qin L; Miao J; Sheng W; Xie Y; Xu X; Yang J; Qian H
Melanoma Res; 2014 Feb; 24(1):20-31. PubMed ID: 24300090
[TBL] [Abstract][Full Text] [Related]
36. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
37. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway.
Long J; Pi X
Biomed Res Int; 2020; 2020():5149417. PubMed ID: 32733943
[TBL] [Abstract][Full Text] [Related]
38. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
39. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
Grzywa TM; Klicka K; Paskal W; Dudkiewicz J; Wejman J; Pyzlak M; Włodarski PK
PLoS One; 2020; 15(6):e0234707. PubMed ID: 32555626
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells.
Zhang J; Hou L; Zhao D; Pan M; Wang Z; Hu H; He J
Clin Transl Oncol; 2017 Nov; 19(11):1358-1374. PubMed ID: 28733866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
